Immy
How we got $812K
Based on typical figures for its industry (2022 Economic Census), not its own records.
What we know
Signs of a sale Some signs of a sale
- In business 47 years (since 1979)
From public records and the company's website, not a statement that it's for sale.
What they do
IMMY is a US-based mycology organization that develops, manufactures, and distributes diagnostic tests and reagents for fungal diseases.
From the company's website. Industry: In-Vitro Diagnostic Substance Manufacturing.
Customers & suppliers
Customers
- Federal University of Ceará · named on its website
- Sao José Hospital · named on its website
- Hospital Madariaga · named on its website
- Instituto Nacional de Higiene Rafael Rangel · named on its website
Compared with similar businesses nearby
| Business | Est. revenue | Distance |
|---|---|---|
| Immy this business | $1.1M | — |
| IMMUNO-MYCOLOGICS, INC. Norman · 82 employees | $62.4M | 0.0 mi |
| AVARA PHARMACEUTICAL SERVICES, INC. Norman | $110.7M | 3.0 mi |
| Avara Pharma Technologies Norman | $3.0M | 5.8 mi |
| SOLIDTECH ANIMAL HEALTH, INC. Newcastle · 10 employees | $6.6M | 6.7 mi |
| Purma Biologics, Llc. Oklahoma City | $2.0M | 9.2 mi |
| HOME CARE PHARMACY, INC. Oklahoma City · 1 employees | $1.2M | 12.0 mi |
The full calculation
Figures are shown toward the upper part of their range rather than at its middle.
Brought up to date assuming revenue has grown 8% a year since 2020, when the PPP figures were reported; included above.
| Estimated value = EBITDA × typical sale multiple | $812K |
| Multiple for this size and industry | 3.8× |
| Value range | $239K – $1.5M |
This business has no PPP loan on record, so there is no business-specific data. The figures are the typical estimated revenue of In-Vitro Diagnostic Substance Manufacturing businesses in our Oklahoma data: the middle value, with the range covering the middle half of those businesses. EBITDA applies the industry margin (20%). Treat these as a rough guide.
| Revenue range | $396K – $1.6M |
| EBITDA range | $78K – $319K |
| Industry (NAICS) | In-Vitro Diagnostic Substance Manufacturing (325413) |
EBITDA margin: from IRS tax returns of S corporations in this industry (2019–2022), adjusted for company size: smaller companies typically run higher margins. EBITDA here is after owners' salaries.
Benchmarks: US Economic Census 2022. These are statistical estimates, not reported financials. Listing details come from Overture Maps open data. Full methodology
History & advisors
From the company's own website and public filings (DOL Form 5500, IRS Form 990, SBA). Roles are as stated there and may be out of date.
Public records
Matched to this business by name and address from public government data; a match can occasionally be wrong.
About Immy
Immy is an in-vitro diagnostic substance manufacturing company in Norman, Oklahoma, in business since 1979. It is owned by Sean Bauman (CEO). Its estimated annual revenue is about $1.1M, with roughly $214K of EBITDA. Its estimated business value is $812K (likely range $239K–$1.5M).
Common questions
- Who owns Immy?
- Immy is owned by Sean Bauman (CEO), according to public sources such as the company's website or filings.
- How much revenue does Immy make?
- SeeBITDA estimates Immy's annual revenue at about $1.1M (likely between $396K and $1.6M), based on public records such as its PPP loan and retirement-plan filings, brought up to 2026.
- What is Immy worth?
- About $812K, roughly 3.8× its estimated EBITDA of $214K, typical for a in-vitro diagnostic substance manufacturing company its size. Likely range: $239K–$1.5M.
- When was Immy founded?
- Immy has been in business since 1979.